Herbs & Supplements

References

Abdel-Salam OM. Anti-inflammatory, antinociceptive, and gastric effects of Hypericum perforatum in rats. ScientificWorldJournal. 2005;5:586-595.

Aggarwal A, Ades PA. Interactions of herbal remedies with prescription cardiovascular medications. Coronary Artery Disease. 2001;12(7):582-584.

Andren L, Andreasson A, Eggertsen R. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. European Journal of Clinical Pharmacology. 2007;63(10):913-916.

Anghelescu IG, Kohnen R, Szegedi A, Klement S, Kieser M. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. Pharmacopsychiatry. 2006;39(6):213-219.

Anon. Final report on the safety assessment of Hypericum perforatum extract and Hypericum perforatum oil. International Journal of Toxicology. 2001;20(Suppl2):31-39.

Anon: St. John's wort. In: DerMarderosian A, Beutler JA, eds. Facts and Comparisons: The Review of Natural Products. St. Louis, MO, Facts and Comparisons. August 2000.

Barnes J, Anderson LA, Phillipson JD. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. Journal of Pharmacy and Pharmacology. 2001;53(5):583-600.

Barnes J, Barber N, Wheatley D, Williamson EM. A pilot randomised [sic], open, uncontrolled, clinical study of two dosages of St John's wort (Hypericum perforatum) herb extract (LI-160) as an aid to motivational/behavioural [sic] support in smoking cessation. Planta Medica. 2006;72(4):378-382.

Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John's wort and cyclosporine. Annals of Pharmacotherapy 2000;34 (9):1013-1016.

Bauer S, Stormer E, Johne A, et al. Alterations in cyclosporin [sic] A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. British Journal of Clinical Pharmacology. 2003;55(2):203-211.

Beattie PE, Dawe RS, Traynor NJ, Woods JA, Ferguson J, Ibbotson SH. Can St John's wort (hypericin) ingestion enhance the erythemal response during high-dose ultraviolet A1 therapy? British Journal of Dermatology. 2005;153(6):1187-1191.

Beckert BW, Concannon MJ, Henry SL, Smith DS, Puckett CL. The effect of herbal medicines on platelet function: an in vivo experiment and review of the literature. Plastic and Reconstructive Surgery. 2007;120(7):2044-2050.

Beckman SE, Sommi RW, Switzer J. Consumer use of St. John's wort: A survey of effectiveness, safety, and tolerability. Pharmacotherapy 2000;20(5):568-574.

Bell EC, Ravis WR, Chan HM, Lin YJ. Lack of pharmacokinetic interaction between St. John's wort and prednisone. Annals of Pharmacotherapy. 2007;41(11):1819-1824.

Bell EC, Ravis WR, Lloyd KB, Stokes TJ. Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. Annals of Pharmacotherapy. 2007;41(2):229-234.

Bennett DA Jr, Phun L, Polk JF, Voglino SA, Zlotnik V, Raffa RB. Neuropharmacology of St. John's Wort (Hypericum). Annals of Pharmacotherapy. 1998 Nov;32(11):1201-1208.

Boiy A, Roelandts R, van den Oord J, de Witte PA. Photosensitizing activity of hypericin and hypericin acetate after topical application on normal mouse skin. British Journal of Dermatology. 2008;158(2):360-369.

Brazier NC, Levine MA. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. American Journal of Therapeutics. 2003;10(3):163-169.

Briese V, Stammwitz U, Friede M, Henneicke-von Zepelin HH. Black cohosh with or without St. John's wort for symptom-specific climacteric treatment--results of a large-scale, controlled, observational study. Maturitas. 2007;57(4):405-414.

Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study. Clinical Therapeutics. 2000;22(4):411-419.

Bressler R. Herb-drug interactions. St. John's wort and prescription medications. Geriatrics. 2005;60(7):21-23.

Brockmoller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry. 1997;30(Suppl 2):94-101.

Butterweck V. Mechanism of action of St John's wort in depression : what is known? CNS Drugs. 2003;17(8):539-562.

Caccia S. Antidepressant-like components of Hypericum perforatum extracts: an overview of their pharmacokinetics and metabolism. Current Drug Metabolism. 2005;6(6):531-543.

Cala S, Crismon ML, Baumgartner J. A survey of herbal use in children with attention-deficit-hyperactivity disorder or depression. Pharmacotherapy. 2003;23(2):222-230.

Calapai G, Crupi A, Firenzuoli F, et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hypericum perforatum. Pharmacopsychiatry 2001;34(2):45-49.

Capasso R, Borrelli F, Aviello G, Capasso F, Izzo AA. Inhibitory effect of the herbal antidepressant St. John's wort (Hypericum perforatum) on rat gastric motility. Naunyn Schmiedebergs Arch Pharmacol. 2008;376(6):407-414.

Catania MA, Firenzuoli F, Crupi A, Mannucci C, Caputi AP, Calapai G. Hypericum perforatum attenuates nicotine withdrawal signs in mice. Psychopharmacology (Berlin). 2003;169(2):186-189.

Cecchini C, Cresci A, Coman MM, et al. Antimicrobial activity of seven hypericum entities from central Italy. Planta Medica. 2007;73(6):564-566.

Cervo L, Rozio M, Ekalle-Soppo CB, Guiso G, Morazzoni P, Caccia S. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology (Berlin). 2002;164(4):423-428.

Chaudhary A, Willett KL. Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John's wort. Toxicology. 2006;217(2-3):194-205.

Chung DJ, Kim HY, Park KH, et al. Black cohosh and St. John's wort (GYNO-Plus) for climacteric symptoms. Yonsei Medical Journal. 2007;48(2):289-294.

Clement K, Covertson CR, Johnson MJ, Dearing K. St. John's wort and the treatment of mild to moderate depression: a systematic review. Holistic Nurse Practitioner. 2006;20(4):197-203.

Coskun I, Tayfun Uzbay I, Ozturk N, Ozturk Y. Attenuation of ethanol withdrawal syndrome by extract of Hypericum perforatum in Wistar rats. Fundamental Clinical Pharmacology. 2006;20(5):481-488.

Cotterill JA. Severe phototoxic reaction to laser treatment in a patient taking St John's Wort. Journal of Cosmetic Laser Therapy. 2001;3(3):159-160.

Cracchiolo C. St. John's wort treatise--part 13. Dosage and administration. No date given. Available at: http://www.dietandbody.com/alternativemedicine/ article1026.html. Accessed August 12, 2003.

Crampsey DP, Douglas CM, Cooke LD. Nasal insertion of St John's wort: an unusual cause of epistaxis. Journal of Laryngology and Otolaryngology. 2007;121(3):279-280.

Das S, Skillington L, Hammett T. St John's wort. Fact sheet #18. The Non-Timber Forest Products Program. Virginia Tech University. January 2001. Available at: http://www.sfp.forprod.vt.edu/factsheets/wort.pdf. Accessed June 6, 2007.

Dasgupta A. Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St. John's wort. Therapeutic Drug Monitoring. 2008;30(2):212-217.

Dasgupta A, Bernard DW. Herbal remedies: effects on clinical laboratory tests. Archives of Pathology and Laboratory Medicine. 2006;130(4):521-528.

Dasgupta A, Hovanetz M, Olsen M, Wells A, Actor JK. Drug-herb interaction: effect of St John's wort on bioavailability and metabolism of procainamide in mice. Archives of Pathology and Laboratory Medicine. 2007;131(7):1094-1098.

Dasgupta A, Tso G, Szelei-Stevens K. St. John's wort does not interfere with therapeutic drug monitoring of 12 commonly monitored drugs using immunoassays. Journal of Clinical Laboratory Analysis. 2006;20(2):62-67.

Davids LM, Kleemann B, Kacerovska D, Pizinger K, Kidson SH. Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. Journal of Photochemistry and Photobiology B. Epublished ahead of print. February 7, 2008.

Davidson JR, Connor KM. St. John's wort in generalized anxiety disorder: three case reports. Journal of Clinical Psychopharmacology. 2001;21(6):635-636.

Dean AJ. Natural and complementary therapies for substance use disorders. Current Opinion on Psychiatry. 2005;18(3):271-276.

Dell'aica I, Caniato R, Biggin S, Garbisa S. Matrix proteases, green tea, and St. John's wort: Biomedical research catches up with folk medicine. Clin Chim Acta. 2007;381(1):69-77.

Dell'aica I, Niero R, Piazza F, et al. Hyperforin blocks neutrophil activation of matrix metalloproteinase-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis. Journal of Pharmacology and Experimental Therapeutics. 2007;321(2):492-500.

Demiroglu YZ, Yeter TT, Boga C, et al. Bone marrow necrosis: a rare complication of herbal treatment with Hypericum perforatum (St. John's wort). Acta Medica (Hradec Kralove). 2005;48(2):91-94.

De Paola R, Muia C, Mazzon E, et al. Effects of Hypericum perforatum extract in a rat model of ischemia and reperfusion injury. Shock. 2005;24(3):255-263.

Di Carlo G, Borelli F, Ernst E, Izzo AA. St John's wort: Prozac from the plant kingdom. Trends in Pharmaceutical Science. 2001;22(6):292-297.

Di Carlo G, Pacilio M, Capasso R, Di Carlo R. Effect on prolactin secretion of Echinacea purpurea, hypericum perforatum and Eleutherococcus senticosus. Phytomedicine. 2005;12(9):644-647.

Dinamarca MC, Cerpa W, Garrido J, Hancke JL, Inestrosa NC. Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. Molecular Psychiatry. 2006;11(11):1032-1048.

Donovan JL, DeVane CL, Lewis JG, et al. Effects of St John's wort (Hypericum perforatum L.) extract on plasma androgen concentrations in healthy men and women: a pilot study. Phytotherapy Research. 2005;19(10):901-906.

Dresser GK, Schwarz UI, Wilkinson GR, Kim RB Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clinical Pharmacology and Therapeutics. 2003;73(1):41-50.

Dugoua JJ, Mills E, Perri D, Koren G. Safety and efficacy of St. John's wort (hypericum) during pregnancy and lactation. Canadian Journal of Clinical Pharmacology. 2006;13(3):e268-e276.

Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). European Journal of Clinical Pharmacology. 1998;54(8):589-594.

Ernst E. St John's Wort supplements endanger the success of organ transplantation. Archives of Surgery. 2002;137(3):316-319.

Etogo-Asse F, Boemer F, Sempoux C, Geubel A. Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts following tibolone and Hypericum perforatum (St. John's wort). Case of drug interaction? Acta Gastroenterol Belg. 2008;71(1):36-38.

Fava M, Alpert J, Nierenberg AA, et al. A double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. Journal of Clinical Psychopharmacology. 2005;25(5):441-447.

Findling RL, McNamara NK, O'Riordan MA, et al. An open-label pilot study of St. John's wort in juvenile depression. Journal of the American Academy of Child and Adolescent Psychiatry. 2003;42(8):908-914.

Fogle RH, Murphy PA, Westhoff CL, Stanczyk FZ. Does St. John's wort interfere with the antiandrogenic effect of oral contraceptive pills? Contraception. 2006;74(3):245-248.

Franklin M, Cowen PJ. Researching the antidepressant actions of Hypericum perforatum (St. John's wort) in animals and man. Pharmacopsychiatry. 2001;34 Suppl 1:S29-S37.

Friede M, Henneicke von Zepelin HH, Freudenstein J. Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort. Pharmacopsychiatry. 2001;34 Suppl 1:S38-S41.

Frost P, Bornstein S, Ehrhart-Bornstein M, et al. The prototypic antidepressant drug, imipramine, but not Hypericum perforatum (St. John's Wort), reduces HPA-axis function in the rat. Hormonal and Metabolic Research. 2003;35(10):602-606.

Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clinical Pharmacology and Therapeutics. 2004;76(4):323-329.

Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355(9198):134-138.

Garrovo C, Rosati A, Bartoli F, Decorti G. St John's wort modulation and developmental expression of multidrug transporters in the rat. Phytotherapy Research. 2006;20(6):468-473.

Gardiner P, Phillips R, Shaughnessy AF. Herbal and dietary supplement--drug interactions in patients with chronic illnesses. American Family Physician. 2008;77(1):73-78.

Gaster B, Holroyd J. St John's wort for depression. Archives of Internal Medicine. 2000;160(2):152-156.

Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised [sic], multicentre [sic], placebo-controlled study. Pharmacopsychiatry. 2006;39(2):66-75.

Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry. 2005;38(2):78-86.

Geller SE, Studee L. Botanical and dietary supplements for menopausal symptoms: what works, what does not. Journal of Womens Health (Larchmont). 2005;14(7):634-649.

Geller SE, Studee L. Botanical and dietary supplements for mood and anxiety in menopausal women. Menopause. 2007;14(3 Pt 1):541-9.

Geller SE, Studee L. Contemporary alternatives to plant estrogens for menopause. Maturitas. 2006;55(Suppl 1):S3-S13.

Genovese T, Mazzon E, Di Paola R, et al. Hypericum perforatum attenuates the development of cerulein-induced acute pancreatitis in mice. Shock. 2006;25(2):161-167.

Genovese T, Mazzon E, Menegazzi M, et al. Neuroprotection and enhanced recovery with hypericum perforatum extract after experimental spinal cord injury in mice. Shock. 2006;25(6):608-617.

Gibbons S, Ohlendorf B, Johnsen I. The genus Hypericum--a valuable resource of anti-Staphylococcal leads. Fitoterapia. 2002 ;73(4):300-304.

Gilani AH, Khan AU, Subhan F, Khan M. Antispasmodic and bronchodilator activities of St John's wort are putatively mediated through dual inhibition of calcium influx and phosphodiesterase. Fundamental and Clinical Pharmacology. 2005;19(6):695-705.

Gobbi M, Moia M, Pirona L, Morizzoni P, Mennini T. In vitro binding studies with two hypericum perforatum extracts--hyperforin, hypericin and biapigenin--on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry. 2001;34(Suppl 1):S45-S48.

Goldman RD, Koren G for the Motherisk Team. Taking St John's wort during pregnancy. Canadian Family Physician. 2003;49:29-30.

Golsch S, Vocks E, Rakoski J, Brockow K, Ring J. Reversible increase in photosensitivity to UV-B caused by St. John's wort extract. [Article in German]. Hautarzt 1997;48(4):249-252.

Groning R, Breitkreutz J, Muller RS. Physico-chemical interactions between extracts of Hypericum perforatum L. and drugs. European Journal of Pharmaceutics and Biopharmaceutics. 2003;56(2):231-236.

Grube B, Walper A, Wheatley D. St. John's Wort extract: efficacy for menopausal symptoms of psychological origin. Advances in Therapeutics. 1999;16(4):177-186.

Gulick RM, McAuliffe V, Holden-Wiltse J, et al. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Annals of Internal Medicine. 1999;130(6):510-514.

Gupta RK, Moller HJ. St. John's Wort. An option for the primary care treatment of depressive patients? European Archives of Psychiatry and Clinical Neuroscience. 2003;253(3):140-148.

Gurley BJ, Gardner SF, Hubbard MA, et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs and Aging. 2005;22(6):525-539.

Gurley BJ, Swain A, Hubbard MA, et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Molecular Nutrition and Food Research. Epublished ahead of print. January 23, 2008.

Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: Comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Molecular Nutrition and Food Research. Epublished ahead of print. January 23, 2008.

Gutmann H, Poller B, Buter KB, Pfrunder A, Schaffner W, Drewe J. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta Medica. 2006;72(8):685-690.

Gutmann H, Poller B, Buter KB, Pfrunder A, Schaffner W, Drewe J. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta Medica. Epublished ahead of print June 1, 2006.

Hall SD, Wang Z, Huang SM, et al. The interaction between St John's wort and an oral contraceptive. Clinical Pharmacology and Therapeutics. 2003;74(6):525-535.

Haller CA, Meier KH, Olson KR. Seizures reported in association with use of dietary supplements. Clinical Toxicology (Philadelphia). 2005;43(1):23-30.

Hammerness P, Basch E, Ulbricht C, et al; for the Natural Standard Research Collaboration. St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003;44(4):271-282.

Hellum BH, Nilsen OG. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clinical Pharmacology and Toxicology. 2008;102(5):466-475.

Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. British Journal of Clinical Pharmacology. 2002;54(4):349-356.

Higuchi A, Yamada H, Yamada E, Jo N, Matsumura M. Hypericin inhibits pathological retinal neovascularization in a mouse model of oxygen-induced retinopathy. Molecular Vision. 2008;14:249-254.

Holden W, Joseph J. Interactions between herbal remedies and antirheumatic drugs. Expert Opinion on Drug Safety. 2005;4(6):969-974.

Hosseinzadeh H, Karimi GR, Rakhshanizadeh M. Anticonvulsant effect of Hypericum perforatum: role of nitric oxide. Journal of Ethnopharmacology. 200598(1-2):207-208.

Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs. 2005;65(9):1239-1282.

Hu Z, Yang X, Ho PC, et al. St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharmaceutical Research. 2005;22(6):902-914.

Hu ZP, Yang XX, Chen X, et al. A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort. Current Drug Metabolism. 2007;8(2):157-171.

Hypericum Depression Trial Study Group. Effect of hypericum perforatum (St John's Wort) in major depressive disorder: A randomized controlled trial. Journal of the American Medical Association. 2002;287(14):1807-1814.

Imai H, Kotegawa T, Tsutsumi K, et al. The recovery time-course of CYP3A after induction by St John's wort administration. British Journal of Clinical Pharmacology. Epublished ahead of print. February 20, 2008.

Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica. 2002;32(6):451-478.

Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. International Journal of Cardiology. 2005;98(1):1-14.

Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001;61(15):2163-2175.

Jacobson JM, Feinman L, Liebes L, et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrobial Agents in Chemotherapy. 2001;45(2):517-524.

Jean D, Pouligon M, Henriot AC. Pharmacological activity of three commercial Hypericum perforatum preparations in mice. Phytotherapy Research. 2006;20(8):653-654.

Jellin JM, Gregory P, Batz F, Hitchens K, et al, eds. Pharmacist's Letter/Prescriber's Letter. Natural Medicines Comprehensive Database, 3rd Edition. Stockton CA: Therapeutic Research Facility, 2000.

Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. British Journal of Clinical Pharmacology. 2004;57(5):592-599.

Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clinical Pharmacology and Therapeutics. 1999;66(4):338-345.

Kacerovska D, Pizinger K, Majer F, Smid F. Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract-a pilot study. Photochemistry and Photobiology. Epublished ahead of print. January 7, 2008.

Kapusta M, Dusek J. Therapeutic and toxicologic aspects of biological effects of Saint John's wort (Hypericum perforatum L.) [Article in Slovak] Ceska Slov Farm. 2003;52(1):20-28.

Kasper S, Anghelescu IG, Szegedi A, Dienel A, Kieser M. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Medicine. 2006;4:14.

Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology (Berlin). 2002;164(3):301-308.

Kasper S, Gastpar M, Muller WE, et al. Efficacy of St. John's wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials. European Archives of Psychiatry and Clinical Neuroscience. 2008;258(1):59-63.

Kim HL, Streltzer J, Goebert D. St. John's wort for depression: A meta analysis of well-defined clinical trials. Journal of Nervous and Mental Diseases. 1999(9);187:532-539.

Klier CM, Schafer MR, Schmid-Siegel B, Lenz G, Mannel M. St. John's wort (Hypericum perforatum)--is it safe during breastfeeding? Pharmacopsychiatry. 2002;35(1):29-30.

Knuppel L, Linde K. Adverse effects of St. John's Wort: a systematic review. Journal of Clinical Psychiatry. 2004;65(11):1470-1479.

Kobak KA, Taylor LV, Bystritsky A, et al. St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. International Clinical Psychopharmacology. 2005;20(6):299-304.

Kumar V, Jaiswal AK, Singh PN, Bhattacharya SK. Anxiolytic activity of Indian Hypericum perforatum Linn: an experimental study. Indian Journal of Experimental Biology. 2000;38(1):36-41.

Kumar V, Singh PN, Bhattacharya SK. Anti-inflammatory and analgesic activity of Indian Hypericum perforatum L. Indian Journal of Experimental Biology. 2001;39(4):339-343.

Laakmann G, Schule C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry. 1998;31(Suppl 1):54-59.

Laggner H, Schreier S, Hermann M, et al. The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug? Free Radical Research. 2007;41(2):234-241.

Lawvere S, Mahoney MC, Cummings KM, et al. A Phase II study of St. John's Wort for smoking cessation. Complementary Therapy in Medicine. 2006;14(3):175-184.

Lawvere S, Mahoney MC. St. John's wort. American Family Physician. 2005;72(11):2249-2254.

Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's Wort Extract WS 5570 in Major Depression: A Double-Blind, Placebo-Controlled Trial. American Journal of Psychiatry. 2002;159(8):1361-1366.

Lee A, Minhas R, Matsuda N, Lam M, Ito S. The safety of St. John's wort (Hypericum perforatum) during breastfeeding. Journal of Clinical Psychiatry. 2003;64(8):966-968.

Linde K, Mulrow CD, Berner M, Egger M. St John's wort for depression. Cochrane Database Systematic Review. April 18, 2005;(2):CD000448.

Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John's wort for depression: an overview and meta-analysis of randomized clinical trials. British Medical Journal 1996;313(7052):253-258.

Lumpkin MM, Alpert S. FDA public health advisory. Subject: Risk Of Drug Interactions With St John's Wort And Indinavir And Other Drugs. February 10, 2000. Available at: http://www.fda.gov/cder/drug/advisory/stjwort.htm. Accessed June 6, 2007.

Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort drug interactions. European Journal of Clinical Pharmacology. 2006;62(3):225-233.

Mai I, Stormer E, Bauer S, Kruger H, Budde K, Roots I. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrology, Dialysis and Transplantation. 2003;18(4):819-822.

Mannel M. Drug interactions with St John's wort : mechanisms and clinical implications. Drug Safety. 2004;27(11):773-797.

Mannucci C, Pieratti A, Firenzuoli F, Caputi AP, Calapai G. Serotonin mediates beneficial effects of Hypericum perforatum on nicotine withdrawal signs. Phytomedicine. 2007;14(10):645-651.

Mansoor GA. Herbs and alternative therapies in the hypertension clinic. American Journal of Hypertension. 2001;14(9 Pt 1):971-975.

Markowitz JS, DeVane CL. The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum). Psychopharmacology Bulletin. 2001;35(1):53-64.

Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. Journal of the American Medical Association. 2003;290(11):1500-1504.

Martinez-Poveda B, Quesada AR, Medina MA. Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process. International Journal of Cancer. 2005;117(5):775-780.

Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. Journal of the National Cancer Institute. 2002;94(16):1247-1249.

Medina MA, Martinez-Poveda B, Amores-Sanchez MI, Quesada AR. Hyperforin: More than an antidepressant bioactive compound? Life Sciences. 2006;79(2):105-111.

Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist. 2006;11(7):742-752.

Menegazzi M, Novelli M, Beffy P, et al. Protective effects of St. John's wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic beta-cell line. International Journal of Biochemistry and Cell Biology. Epublished ahead of print. December 8, 2007.

Miller AL. St. John's Wort (Hypericum perforatum): clinical effects on depression and other conditions. Alternative Medicine Review. 1998;3(1):18-26.

Mills E, Montori V, Perri D, Phillips E, Koren G. Natural health product-HIV drug interactions: a systematic review. International Journal of STD and AIDS. 2005 ;16(3):181-186.

Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Psychiatric Clinics of North America. 2007;30(1):51-68.

Miskovsky P. Hypericin--a new antiviral and antitumor photosensitizer: mechanism of action and interaction with biological macromolecules. Current Drug Targets. 2002;3(1):55-84.

Mohanasundari M, Sabesan M. Modulating effect of Hypericum perforatum extract on astrocytes in MPTP induced Parkinson's disease in mice. European Review of Medical Pharmacology and Science. 2007;11(1):17-20.

Moreno RA, Teng CT, Almeida KM, Tavares Junior H. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. Rev Bras Psiquiatr. 2006 Mar;28(1):29-32.

Mueller SC, Majcher-Peszynska J, Uehleke B, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. European Journal of Clinical Pharmacology. 2006 Jan;62(1):29-36.

Muller WE, Singer A, Wonnemann M. Mechanism of action of St. Johns wort extract. [Article in German] Schweiz Rundsch Med Prax. 2000;89(50):2111-2121.

Murakami Y, Tanaka T, Murakami H, Tsujimoto M, Ohtani H, Sawada Y. Pharmacokinetic modelling [sic] of the interaction between St John's wort and ciclosporin [sic] A. British Journal of Clinical Pharmacology. 2006;61(6):671-676.

Murck H. Atypical depression and related illnesses--neurobiological principles for their treatment with Hypericum extract. [Article in German] Wiener Medizinische Wochenschrift. 2002;152(15-16):398-403.

Murphy PA. St. John's wort and oral contraceptives: reasons for concern? Journal of Midwifery and Womens Health. 2002;47(6):447-450.

Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005;71(6):402-40.

Murray L. Serotonin syndrome. International Programme on Chemical Safety (IPCS) INTOX. March 1999. Available at: http://www.intox.org/pagesource/treatment/english/serotoninsyndrome.htm. Accessed August 12, 2003.

Nangia M, Syed W, Doraiswamy PM. Efficacy and safety of St. John's wort for the treatment of major depression. Public Health and Nutrition. 2000;3(4A):487-494.

National Center for Complimentary and Alternative Medicine. U.S. National Institutes of Health. Questions and answers: a trial of St. John's wort (Hypericum perforatum) for the treatment of major depression. [press release] April 9, 2002. Available at: http://nccam.nih.gov/news/2002/stjohnswort/q-and-a.htm. Accessed June 6, 2007.

National Center for Complementary and Alternative Medicine. St. John's wort vs. placebo in obsessive-compulsive disorder. Last reviewed March 2003. Available at: http://www.clinicaltrials.gov/ct/show/NCT00035438?order=6. Accessed August 20, 2003.

National Center for Complementary and Alternative Medicine. St. John's wort vs. placebo in social phobia. Last reviewed March 2003. Available at: http://www.clinicaltrials.gov/ct/show/NCT00035412?order=5. Accessed August 20, 2003.

National Institutes of Health. National Institute of Mental Health. National Center for Complementary and Alternative Medicine. Office of Dietary Supplements. Treatment of minor depression. [press release] March 21, 2003. Available at: http://www.nimh.nih.gov/events/prminordep.cfm. Accessed April 11, 2003.

Nordfors M, Hartvig P. St John's wort against depression in favour again. [Article in Swedish] Lakartidningen. 1997;94(25):2365-2367.

Nowack R. Cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort - and beyond! Nephrology (Carlton). Epublished ahead of print. March 17, 2008.

Ondrizek RR, Chan PJ, Patton WC, King A. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. Fertility and Sterility. 1999;71(3):517-522.

Ondrizek RR, Chan PJ, Patton WC, King A. Inhibition of human sperm motility by specific herbs used in alternative medicine. Journal of Assisted Reproductive Genetics. 1999;16(2):87-91.

Oubre AY. Hypericin: an active antiviral principle of St. John's wort. German Hepatitis C Forum. No date given. Available at: http://hepatitis-c.de/hyperic.htm. Accessed August 11, 2003.

Ozturk N, Korkmaz S, Ozturk Y. Wound-healing activity of St. John's Wort (Hypericum perforatum L.) on chicken embryonic fibroblasts. Journal of Ethnopharmacology. 2007;111(1):33-39.

Papakostas GI, Crawford CM, Scalia MJ, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology. 2007;56(2-3):132-137.

Parker V, Wong AH, Boon HS, Seeman MV. Adverse reactions to St John's Wort. Canadian Journal of Psychiatry. 2001;46(1):77-79.

Perfumi M, Mattioli L, Cucculelli M, Massi M. Reduction of ethanol intake by chronic treatment with Hypericum perforatum, alone or combined with naltrexone in rats. Journal of Psychopharmacology. 2005;19(5):448-454.

Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. British Journal of Clinical Pharmacology. 2003;56(6):683-690.

Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomized mulicentre study of treatment for eight weeks. British Medical Journal. 1999;319(7224):1534-1539.

Poldinger W. History of St. Johns wort. [Article in German] Schweiz Rundsch Med Prax. 2000;89(50):2102-2109.

Randlov C, Mehlsen J, Thomsen CF, Hedman C, von Fircks H, Winther K. The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. Phytomedicine. 2006;13(4):215-221.

Raso GM, Pacilio M, Di Carlo G, Esposito E, Pinto L, Meli R. In-vivo and in-vitro anti-inflammatory effect of Echinacea purpurea and Hypericum perforatum. Journal of Pharmacy and Pharmacology. 2002;54(10):1379-1383.

Rengelshausen J, Banfield M, Riedel KD, et al. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clinical Pharmacology and Therapeutics. 2005;78(1):25-33.

Rezvani AH, Overstreet DH, Perfumi M, Massi M. Plant derivatives in the treatment of alcohol dependency. Pharmacology, Biochemistry and Behavior. 2003;75(3):593-606.

Rodriguez-Landa JF, Contreras CM. A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine. 2003;10(8):688-699.

Roz N, Mazur Y, Hirshfeld A, Rehavi M. Inhibition of vesicular uptake of monoamines by hyperforin. Life Sciences. 2002 ;71(19):2227-2237.

Saeed SA, Bloch RM, Antonacci DJ. Herbal and dietary supplements for treatment of anxiety disorders. American Family Physician. 2007;76(4):549-556.

Sardella A, Lodi G, Demarosi F, Tarozzi M, Canegallo L, Carrassi A. Hypericum perforatum extract in burning mouth syndrome: a randomized placebo-controlled study. Journal of Oral Pathology and Medicine. Epublished ahead of print. March 6, 2008.

Sarino LV, Dang KH, Dianat N, et al. Drug interaction between oral contraceptives and St. John's Wort: appropriateness of advice received from community pharmacists and health food store clerks. Journal of the American Pharmacists Association (Washington DC). 2007;47(1):42-47.

Sarris J. Herbal medicines in the treatment of psychiatric disorders: a systematic review. Phytotherapy Research. 2007;21(8):703-716.

Savikin K, Dobric S, Tadic V, Zdunic G. Antiinflammatory activity of ethanol extracts of Hypericum perforatum L., H. barbatum Jacq., H. hirsutum L., H. richeri Vill. and H. androsaemum L. in rats. Phytotherapy Research. 2007;21(2):176-180.

Schempp CM, Windeck T, Hezel S, Simon JC. Topical treatment of atopic dermatitis with St. John's wort cream--a randomized, placebo controlled, double blind half-side comparison. Phytomedicine. 2003;10(Suppl 4):31-37.

Schempp CM, Winghofer B, Muller K, Schulte-Monting J, Mannel M, Schopf E, Simon JC. Effect of oral administration of Hypericum perforatum extract (St. John's Wort) on skin erythema and pigmentation induced by UVB, UVA, visible light and solar simulated radiation. Phytotherapy Research. 2003;17(2):141-146.

Schey KL, Patat S, Chignell CF, Datillo M, Wang RH, Roberts JE. Photooxidation of lens alpha-crystallin by hypericin (active ingredient in St. John's Wort). Photochemistry and Photobiology. 2000;72(2):200-203.

Schulz HU, Schurer M, Bassler D, Weiser D. Investigation of the effect on photosensitivity following multiple oral dosing of two different hypericum extracts in healthy men. Arzneimittelforschung. 2006;56(3):212-221.

Schulz V. Clinical trials with hypericum extracts in patients with depression--results, comparisons, conclusions for therapy with antidepressant drugs. Phytomedicine. 2002;9(5):468-474.

Schulz V. Safety of St. John's Wort extract compared to synthetic antidepressants. Phytomedicine. 2006;13(3):199-204.

Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's Wort in major depression: A randomized controlled trial. Journal of the American Medical Association. 2001;285(15):1978-1986.

Shibayama Y, Kawachi A, Onimaru S, et al. Effect of pre-treatment with St John's Wort on nephrotoxicity of cisplatin in rats. Life Sciences. 2007;81(2):103-108.

Simeon J, Nixon MK, Milin R, Jovanovic R, Walker S. Open-label pilot study of St. John's wort in adolescent depression. Journal of Child and Adolescent Psychopharmacology. 2005;15(2):293-301.

Singer A, M. Wonnemann M, Muller WE. Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na+1 1. Journal of Pharmacology and Experimental Therapeutics. 1999;290(3):1363-1368.

Singh YN. Potential for interaction of kava and St. John's wort with drugs. Journal of Ethnopharmacology. 2005;100(1-2):108-113.

Skalkos D, Gioti E, Stalikas CD, Meyer H, Papazoglou TG, Filippidis G. Photophysical properties of Hypericum perforatum L. extracts--novel photosensitizers for PDT. Journal of Photochemistry and Photobiology. B: Biology. 2006;82(2):146-151.

Skalkos D, Stavropoulos NE, Tsimaris I, et al. The lipophilic extract of Hypericum perforatum exerts significant cytotoxic activity against T24 and NBT-II urinary bladder tumor cells. Planta Medica. 2005;71(11):1030-1035.

Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy. 2004;24(11):1508-1514.

Sosa S, Pace R, Bornancin A, et al. Topical anti-inflammatory activity of extracts and compounds from Hypericum perforatum L. Journal of Pharmacy and Pharmacology. 2007;59(5):703-709.

Southwell IA, Bourke CA. Seasonal variation in hypericin content of Hypericum perforatum L. (St. John's Wort). Phytochemistry. 2001;56(5):437-441.

Spinella M. Herbal medicines and epilepsy: the potential for benefit and adverse effects. Epilepsy and Behavior. 2001;2(6):524-532.

Stavropoulos NE, Kim A, Nseyo UU, et al. Hypericum perforatum L. extract - Novel photosensitizer against human bladder cancer cells. Journal of Photochemistry and Photobiology. B: Biology. 2006;84(1):64-69.

Stevinson C, Ernst E. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. British Journal of Obstetrics and Gynaecology. 2000 Jul;107(7):870-876.

Stevinson C, Ernst E. Hypericum for depression. An update of the clinical evidence. European Neuropsychopharmacology. 1999;9(6):501-505.

Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clinical Pharmacology and Therapeutics. 2001;70(6):518-524.

Taylor LH, Kobak KA. An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2000;61(8):575-578.

Tedeschi E, Menegazzi M, Margotto D, Suzuki H, Forstermann U, Kleinert H. Anti-inflammatory actions of St. John's wort: inhibition of human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of transcription-1alpha (STAT-1alpha) activation. Journal of Pharmacology and Experimental Therapeutics. 2003;307(1):254-261.

Tesch BJ. Herbs commonly used by women: an evidence-based review. Disease of the Month. 2002;48(10):671-696.

Turton-Weeks SM, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. St. John's wort: a hidden risk for transplant patients. Progress in Transplantation. 2001;11(2):116-120.

Uchida S, Hirai K, Hatanaka J, Hanato J, Umegaki K, Yamada S. Antinociceptive effects of St. John's wort, Harpagophytum procumbens extract and grape seed proanthocyanidins extract in mice. Biology and Pharmacy Bulletin. 2008;31(2):240-245.

Uebelhack R, Blohmer JU, Graubaum HJ, Busch R, Gruenwald J, Wernecke KD. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstetrics and Gynecology. 2006;107(2 Pt 1):247-255.

Uzbay TI. Hypericum perforatum and substance dependence: a review. Phytotherapy Research. Epublished ahead of print. March 18, 2008.

Uzbay IT, Coskun I, Kayir H, Ozturk N, Ozturk Y. Extract of Hypericum perforatum blocks caffeine-induced locomotor activity in mice: a possible role of nitric oxide. Phytotherapy Research. 2007;21(5):415-419.

Vandenbogaerde A, Zanoli P, Puia G, et al. Evidence that total extract of Hypericum perforatum affects exploratory behavior and exerts anxiolytic effects in rats. Pharmacology, Biochemistry and Behavior. 2000;65(4):627-633.

Vitiello B, Shader RI, Parker CB, et al. Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial. Journal of Clinical Psychopharmacology. 2005;25(3):243-249.

Volz HP, Murck H, Kasper S, Moller HJ. St. John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berlin). 2002;164(3):294-300.

Volz HP. Controlled clinical trials of hypericum extracts in depressed patients - an overview. Pharmacopsychiatry. 1997;30(Suppl 2):72-76.

Wang LS, Zhou G, Zhu Bet al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clinical Pharmacology and Therapeutics. 2004;75(3):191-197.

Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology and Therapeutics. 2001;70(4):317-326.

Weber CC, Eckert GP, Muller WE. Effects of antidepressants on the brain/plasma distribution of corticosterone. Neuropsychopharmacology. 2006;31(11):2443-2448.

Werneke U, Turner T, Priebe S. Complementary medicines in psychiatry: review of effectiveness and safety. British Journal of Psychiatry. 2006;188:109-121.

Wheatley D. Hypericum in seasonal affective disorder (SAD). Current Medical Research and Opinion. 1999;15(1):33-37.

Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. International Clinical Psychopharmacology. 2001;16(5):239-252.

Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. British Journal of Clinical Pharmacology. 2006;62(5):512-526.

Wielgus AR, Chignell CF, Miller DS, et al. Phototoxicity in human retinal pigment epithelial cells promoted by hypericin, a component of St. John's wort. Photochemistry and Photobiology. 2007;83(3):706-713.

Woelk H. for the Remotiv/Imipramine Study Group. Comparison of St John's wort and imipramine for treating depression: randomised [sic] controlled trial. British Medical Journal. 2000;321(7260):536-539.

Wright CW, Gott M, Grayson B, et al. Correlation of hyperforin content of Hypericum perforatum (St John's Wort) extracts with their effects on alcohol drinking in C57BL/6J mice: a preliminary study. Journal of Psychopharmacology. 2003;17(4):403-408.

Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a 'modern' herbal antidepressant : pharmacokinetics of active ingredients. Clinical Pharmacokinetics. 2006;45(5):449-468.

Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John's wort. Journal of Psychopharmacology. 2004;18(2):262-276.

Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metabolism Review. 2003;35(1):35-98.

Zou Y, Lu Y, Wei D. Hypocholesterolemic effects of a flavonoid-rich extract of Hypericum perforatum L. in rats fed a cholesterol-rich diet. Journal of Agricultural and Food Chemistry. 2005;53(7):2462-2466.

Last Revised April 18, 2008